| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5892394 | Bone | 2010 | 5 Pages |
Abstract
The measurement of urinary NTX by POCD appears to be a viable option for the monitoring of metastatic cancer patients. Whilst POCDs appear to record higher values than laboratory assays, the correlation between devices is good and with further research the NTX categories could be modified to accommodate this variation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Jim E. Lester, Janet E. Brown, Rosemary A. Hannon, Sue P. Ellis, Janet M. Horsman, Omprakash P. Purohit, Robert E. Coleman,